Pasithea Therapeutics Corp. (KTTA): Nasdaq/NYSE listing notice — Pasithea Therapeutics receives Nasdaq extension to Jan 15, 2024 for bid price compliance

Pasithea Therapeutics Corp.

Nasdaq granted 180-day extension to January 15, 2024 to regain $1.00 minimum bid price compliance.
Previous non-compliance notice received Jan 19, 2023; extension granted Jul 19, 2023 to Jan 15, 2024.
Company may consider reverse stock split; no assurance of regaining compliance.
Failure to comply by deadline may result in Nasdaq delisting notice; Company can appeal.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Pasithea Therapeutics Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

July 19, 2023, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to January 15, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will pro

View on SEC.gov

16 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Pasithea Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001213900-23-058326

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.